Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

Biotechnology

Healthcare
$7.38 -2.78%

-$0.15 today

Market cap
$2.10B
Beta
0.71
P/E (TTM)
-7.1
EPS (TTM)
-$0.71
52W Low $1.99High $5.32

Volume 1.41M

Average 2.42M

MRVI Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 40.1%

Gross margin was 40.1% in Q2 FY2026, up 23.8 pp from a year earlier. On a trailing-twelve-month basis it was 34.6%, up 5.5 pp year over year. Over 3 fiscal years it narrowed by 62.9 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
40.1%-11.0 pp QoQ
Last fiscal yearDec 2025
18.0%-23.8 pp YoY
LTMJun 2026
34.6%+5.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+23.8 pp——
1 year-23.8 pp——
3 years-62.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
18.0%
Year-over-year change
-23.8pp

Gross Margin vs competitors

How MRVI compares with its peers on the latest reported figures

  • MRVI's LTM Jun 2026 gross margin of 34.6% is the lowest of the 9 companies compared; the peer median is 49.7%.
  • Its year-over-year change of +5.5 pp is the 4th highest of 9, against a peer median of -0.3 pp.
  • Over three fiscal years its change of -62.9 pp compares with a peer median of -2.2 pp.
MRVI Competitors Peer median
Gross Margin for MRVI and competitors
Company Period LTM level YoY 3-year change
TECHBio-Techne CorporationLTM Sep 202665.8% +0.4 pp-2.0 pp
BLFSBioLife Solutions, Inc.LTM Mar 202663.9% -19.5 pp+3.0 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202651.9% -0.9 pp-3.9 pp
RGENRepligen CorporationLTM Jun 202651.1% +6.8 pp-9.8 pp
LABStandard BioTools Inc.LTM Mar 202648.3% -1.2 pp+12.0 pp
NEOGNeogen CorporationLTM Aug 202647.4% +6.3 pp-2.4 pp
AZTAAzenta, Inc.LTM Sep 202644.2% -2.0 pp+9.2 pp
PACBPacific Biosciences of California, Inc.LTM Mar 202637.1% +20.9 pp-6.5 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 202634.6% +5.5 pp-62.9 pp
Peer median (excluding MRVI) 49.7%-0.3 pp-2.2 pp

Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue799.24M883M288.95M259.19M185.74M
Cost of Revenue140.56M168.96M148.74M150.88M152.35M
Gross Profit658.68M714.04M140.2M108.31M33.39M
Gross Margin82.4%80.9%48.5%41.8%18.0%
Research & Development15.22M18.37M17.28M19.22M23.33M
Selling, General & Admin100.06M129.26M151.39M161.77M171.47M
Operating Expenses104.03M139.83M171.85M343.93M40.13M
Depreciation & Amortization24.75M38.1M48.78M56.87M60.47M
EBITDA585.78M609.99M712.41M(156.92M)(147.51M)
EBITDA Margin73.3%69.1%246.6%-60.5%-79.4%
Operating Income554.65M574.22M(31.65M)(235.62M)(6.74M)
Operating Margin69.4%65.0%-11.0%-90.9%-3.6%
Interest Income02.34M27.73M27.4M23.95M
Interest Expense30.26M20.41M45.89M47.7M26.99M
Other Income / Expenses(23.88M)(22.74M)649.38M(25.87M)(228.24M)
Income Before Tax530.77M551.47M617.74M(261.48M)(234.97M)
Pre-Tax Margin66.4%62.5%213.8%-100.9%-126.5%
Income Tax Expense61.52M60.81M756.11M(1.86M)(4.21M)
Net Income182.04M220.21M(119.03M)(144.85M)(130.77M)
Net Margin22.8%24.9%-41.2%-55.9%-70.4%
EPS (Basic)1.591.67(0.90)(1.05)(0.91)
EPS (Diluted)1.561.67(0.90)(1.05)(0.91)
Weighted Avg Shares114.79M131.54M131.92M137.91M145.07M
Weighted Avg Shares (Diluted)121.97M131.7M131.92M137.91M145.07M

Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

Intrinsic Alpha fair value

Locked

Current Price

$7.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.